

Auswahl an Publikationen (Pubmed unter Bogner C)

- Allosteric regulation of BH3 proteins in Bcl-XL complexes confers switch-like activation of Bax. Bogner C, Kale J, Chi X, Shamas-Din A, Fradin C, Leber B and Andrews D. *Molecular Cell* 77, 1-12 February 20, 2020.
- Apoptosis: embedded in membranes. Bogner C, Leber B, Andrews DW. *Curr Opin Cell Biol.* 2010 Dec;22(6):845-51. Epub 2010 Aug 26.
- Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. Bogner C, Dechow T, Ringshausen I, Wagner M, Oelsner M, Lutzny G, Licht T, Peschel C, Pastan I, Kreitman RJ, Decker T. *Br J Haematol.* 2010 Jan;148(1):99-109. Epub 2009 Oct 11.
- Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach. Bogner C, Peschel C, and Decker T. *Leukemia & Lymphoma*, February 2006; 47(2): 195 – 205.
- CyclinE but not bcl-2, bax or mcl-1 is differentially expressed in ZAP-70 positive and negative CLL cells. Bogner C, Michael Sandherr, Michael Perker, Katrin Weick, Ingo Ringshausen, Christian Peschel and Thomas Decker. *Ann Hematol*, 2006, 2 DOI 10.1007/s00277-005- 0076-y
- Cycling CLL cells are highly susceptible to inhibition of the proteasome: Involvement of p27, early D-type cyclins, Bax, and caspase- dependent and - independent pathways. Bogner C, Schneller F, Hipp S, Ringshausen I, Peschel C, and Decker T. *Exp Hematol* 31 (2003) 218-225
- Inhibition of the proteasome induces cell cycle arrest and apoptosis in Mantle cell lymphoma cells. Bogner C, Ringshausen I, Schneller F, Fend F, Quintanilla-Martinez L, Häcker G, Peschel C, and Decker T. *British Journal of Hematology* 122 (2003) 260–268

Buchkapitel

- 2019: TZM Manual Maligne Lymphome, Letztautor – Kapitel Diffus großzelliges Lymphom, Erstautor - Kapitel Burkitt Lymphom, Letztautor - Kapitel HIV assoziierte Lymphome, Coautor – Kapitel Hodgkin Lymphome, Coautor – Kapitel CLL, Coauthor- Kapitel PET Diagnostik
- 2019: TZM Jahrbuch 2019, Kapitel Aggressive Lymphome
- 2015: TZM Manual Maligne Lymphome, Coautor- Kapitel CLL

Vorträge

- 2018-2020 Klinische Vorträge:
 - Post Ash Aggressive Lymphome 01/2020, Klinikum RDI, TUM
 - Post Lugano DLBCL 07/2019, Klinikum Großhadern, LMU
 - Post Ash Aggressive Lymphome 01/2019, Klinikum Großhadern, LMU
 - Post ASCO GIST 07/2018, Klinikum Großhadern, LMU
- 1999-2020 Wissenschaftliche Vorträge:
 - Research in Progress Plattform, 3. Medizinische Klinik, 1999-2019
 - ECDO Konferenz Genf, Schweiz, 10/2015 (eingeladener Sprecher)

- DGHO Jahrestreffen Basel, Schweiz, 10/2015
- Jahrestreffen DACH Konsortium, Obergurgl, Österreich, 03/2015 (eingeladener Sprecher)
- Biological Sciences Platform, Sunnybrook Research Institute, Toronto, Canada, 07/2013
- McMaster University, Hamilton, Kanada, 2009
- Ann Arbor, U.S.A., 2009
- St. Jude Hospital, Memphis, U.S.A., 2009
- Berkley University, U.S.A., 2009
- UCSF, San Francisco, U.S.A., 2009
- Stanford University, Stanford, U.S.A., 2009
- Princeton University, Princeton, U.S.A., 2009
- Posterpräsentationen

2000-2020 Diverse Posterpräsentationen:

- DGHO Jahresversammlung 2000-2019
- CCRC Annual Meeting, Toronto, Kanada, 2011
- ECDO Jahrestreffen, Genf, Schweiz, 2015